[1] Liu H.Emerging agents and regimens for AML[J].Journal of Hematology & Oncology,2021,14(1):49. [2] Yang F,Long N,Anekpuritanang T,et al.Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML[J].Blood,2022,139(8):1208-1221. [3] Lu Y,Yang L,Shen M,et al.Tespa1 facilitates hematopoietic and leukemic stem cell maintenance by restricting c-Myc degradation[J].Leukemia,2023,37(5):1039-1047. [4] Mill C P,Fiskus W,Das K,et al.Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1[J].Leukemia,2023,37(6):1336-1348. [5] Cappelli L V,Meggendorfer M,Baer C,et al.Indeterminate and oncogenic potential:CHIP vs CHOP mutations in AML with NPM1 alteration[J].Leukemia,2022,36(2):394-402. [6] Sabatier M,Birsen R,Lauture L,et al.C/EBPα confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3 -mutant leukemia[J].Cancer Discovery,2023,13(7):1720-1747. [7] Greve G,Andrieux G,Schlosser P,et al.In vivo kinetics of early,non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts[J].Leukemia,2023,37(5):1018-1027. [8] Deshpande A J,Zhu N.Silencing with SAFB:a new role for HOXA9 in AML[J].Blood,2023,141(14):1653-1655. [9] Levavasseur F,Oussous S,Zubaidan T,et al.FOXP1 regulates oxidative stress,SIRT1 expression,and resistance to chemotherapies in acute myeloid leukemia cells[J].Blood Advances,2023,7(13):3265-3275. [10] Eriksson A,Engvall M,Mathot L,et al.Somatic exonic deletions in RUNX1 constitutes a novel recurrent genomic abnormality in acute myeloid leukemia[J].Clinical Cancer Research,2023:1-9. [11] Cortes J E,Lin T L,Asubonteng K,et al.Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by european leukemiaNet 2017 risk subgroups in older adults with newly diagnosed,high-risk/secondary AML:post hoc analysis of a randomized,phase 3 trial[J].Journal of Hematology & Oncology,2022,15(1):155. [12] Gonskikh Y,Stoute J,Shen H,et al.Noncatalytic regulation of 18 S rRNA methyltransferase DIMT1 in acute myeloid leukemia[J].Genes & Development,2023,37(7-8):321-335. [13] Esperanza-Cebollada E,Gomez-Gonzalez S,Perez-Jaume S,et al.A miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemia[J].British Journal of Haematology,2023,202(1):96-110. [14] Palam L R,Ramdas B,Pickerell K,et al.Loss of Dnmt3a impairs hematopoietic homeostasis and myeloid cell skewing via the PI3Kinase pathway[J].CI Insight,2023,8(9):e163864. [15] Murdock H M,Kim H T,Denlinger N,et al.Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML[J].Blood,2022,139(24):3546-3557. [16] Sekeres M A,Guyatt G,Abel G,et al.American society of hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults[J].Blood Advances,2020,4(15):3528-3549. [17] Zhao Y,Simon M,Seluanov A,et al.DNA damage and repair in age-related inflammation[J].Nature Reviews Immunology,2023,23(2):75-89. [18] Zhang J,Hu X,Wang J,et al.Immune receptor repertoires in pediatric and adult acute myeloid leukemia[J].Genome Medicine,2019,11(1):73.
2024, Vol. 30 
冀公网安备13080202000677号